David Risinger
Stock Analyst at Leerink Partners
(4.51)
# 209
Out of 4,827 analysts
169
Total ratings
65.17%
Success rate
13.26%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Downgrades: Market Perform | $550 → $503 | $429.60 | +17.09% | 4 | May 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $547.67 | +52.28% | 8 | Feb 5, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $182 → $169 | $155.66 | +8.57% | 3 | Jan 23, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $185.58 | +11.00% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $46.88 | +55.72% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $21.02 | +228.26% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $5.82 | +174.91% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $9.75 | +351.28% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $31.45 | +386.49% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $9.90 | +1.01% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $2 | $1.91 | +4.71% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $19.58 | +140.04% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $272.05 | +16.89% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $12.39 | -11.22% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $751.45 | -39.05% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $67.73 | -37.99% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $98.16 | -7.29% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $22.97 | +108.97% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $11.03 | -9.34% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $10 | $29.38 | -65.96% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $9.02 | +310.20% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $98.41 | +78.84% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $9.09 | +76.02% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $26.80 | +67.91% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $4.70 | +644.68% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $12.28 | +233.88% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $161.69 | +7.61% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $33.10 | +54.08% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $18.07 | -55.73% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $77.65 | +14.62% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $7.46 | -59.79% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $30.38 | -47.33% | 9 | Apr 2, 2020 |
Vertex Pharmaceuticals
May 6, 2025
Downgrades: Market Perform
Price Target: $550 → $503
Current: $429.60
Upside: +17.09%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $547.67
Upside: +52.28%
Johnson & Johnson
Jan 23, 2025
Maintains: Outperform
Price Target: $182 → $169
Current: $155.66
Upside: +8.57%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $185.58
Upside: +11.00%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $46.88
Upside: +55.72%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $21.02
Upside: +228.26%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $5.82
Upside: +174.91%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $9.75
Upside: +351.28%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $31.45
Upside: +386.49%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $9.90
Upside: +1.01%
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $1.91
Upside: +4.71%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $19.58
Upside: +140.04%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $272.05
Upside: +16.89%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $12.39
Upside: -11.22%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $751.45
Upside: -39.05%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $67.73
Upside: -37.99%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $98.16
Upside: -7.29%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $22.97
Upside: +108.97%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $11.03
Upside: -9.34%
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $29.38
Upside: -65.96%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $9.02
Upside: +310.20%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $98.41
Upside: +78.84%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $9.09
Upside: +76.02%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $26.80
Upside: +67.91%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $4.70
Upside: +644.68%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $12.28
Upside: +233.88%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $161.69
Upside: +7.61%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $33.10
Upside: +54.08%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $18.07
Upside: -55.73%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $77.65
Upside: +14.62%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $7.46
Upside: -59.79%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $30.38
Upside: -47.33%